Luis M. Alvarez, MD, a board-certified intensivist, earned his medical degree from Universidad Peruana Cayetano Heredia in Lima, Peru in 2000. From 2000-2002, Dr. Alvarez was in charge of the tuberculosis screening campaign among healthcare workers at the Hospital Nacional Cayetano Heredia in Lima. From 2001-2002, he analyzed the database for trends in drug resistance, failure rates and death rates related to tuberculosis for the Department of Health in Lima. During this time, he was part of a working group tasked with writing the application to the Global Fund to Fight AIDS, Tuberculosis and Malaria. Dr. Alvarez then went on to Emory University in Atlanta, where he completed his residency in internal medicine in 2005. He also completed a fellowship in pulmonary diseases and critical care medicine at the University of California, San Diego in 2008. From 2008 to 2012, Dr. Alvarez served as assistant professor of medicine at the Medical College of Wisconsin in Milwaukee, in the Division of Pulmonary Diseases and Critical Care Medicine. During this time, he was appointed to work at the Clement Zablocki Veterans Affairs Medical Center and the Froedtert Memorial Lutheran Hospital. From 2012 to 2015, Dr. Alvarez served as assistant professor of medicine at the University of Miami Miller School of Medicine in the areas of pulmonary diseases, critical care, allergy and sleep medicine, and internal medicine; and he was appointed to work at University of Miami Hospital.

In 2015, Dr. Alvarez joined Memorial Healthcare System, as an esteemed member of the Memorial Physician Group in the Division of Critical Care Medicine. 

Related Medical Services

• Critical Care

Hospital Affiliations

• Memorial Hospital Miramar
• Memorial Hospital Pembroke
• Memorial Hospital West
• Memorial Regional Hospital

Gender

• Male

Languages

• Spanish
• English

Education

Universidad Peruana Cayetano Heredia, 2000

Internships

Emory University, 2003, Internal Medicine

Residency

Emory University, 2005, Internal Medicine

Fellowships

University Of California San Diego Med Ctr, 2008, Pulmonary Disease

Certifications

American Board of Internal Medicine-Critical Care Medicine
American Board of Internal Medicine-Internal Medicine
American Board of Internal Medicine-Pulmonary Disease

Publications

• C Kytasty, CY Lin, LM Alvarez, A Chan, MA Ferrada, PW Finn, TD Bigby. Interferon β Attenuates Airway Hyperresponsiveness and Allergic Inflammation in a Mouse Asthma Model. American Journal of Respiratory and Critical Care Medicine, 175:A504, 2007.
• Carbajal J, Melgarejo C, Leey J, Dulanto R, Sánchez-Sierra M, Kanamori M, Alvarez LM, Hernández K, Accinelli R. Acute Mountain Sickness among Peruvian Children. American Journal of Respiratory and Critical Care Medicine, 167:A925, 2003.    
• Accinelli R, Pro L, Reyes M, Salazar J, Chiarella P, Guio H, Alvarez LM. The creation of a pilot asthma program decreases pneumonia rates. American Journal of Respiratory and Critical Care Medicine, 165:A745, 2002.
• Accinelli RA, Alvarez LM, Valles PM, Guio H, Munoz P. Annual risk of tuberculosis infection among medical students of Universidad Peruana Cayetano Heredia in Lima-Peru. American Journal of Respiratory and Critical Care Medicine 165:A439, 2002
• Accinelli RA, Hernandez K, Alvarez LM, Pantoja C, Vidal L, Ibanez R, Hinojosa G, Robles L. Risk factors for failing, dying and defaulting among TB patients treated with DOTs. American Journal of Respiratory and Critical Care Medicine, 165:A439, 2002.
• Accinelli RA, Alvarez LM, Chirinos E, Amat O, Hernandez K. Effectiveness of DOTs for new tuberculosis cases in Peru. American Journal of Respiratory and Critical Care Medicine, 165:A291, 2002.
• Accinelli RA, Alvarez LM, Chirinos E, Amat O, Hernandez K. Effectiveness of the retreatment scheme 1 HRZES / 2 HRZE / 5 H2R2E2 for patients who have failed to DOTs. American Journal of Respiratory and Critical Care Medicine,  165:A291, 2002.
• Alvarez LM, Accinelli RA, Hernandez K, Diaz J, Salazar D, Gayoso O. Daily three months isoniazid prevents PPD conversion among preschool contacts of a known tuberculosis case in a hospital’s day care center in Lima, Peru. American Journal of Respiratory and Critical Care Medicine, 165:A291, 2002.
• Accinelli RA, Alvarez LM, Chirinos E, Amat O, Hernandez K, Portocarrero J. Treatment of failing tuberculosis cases to 1 HREZS / 2 HREZ / 5 H2R2E2 with            3 KCxEtZE / 15 CxEtZE in Peru. American Journal of Respiratory and Critical Care Medicine 165:A18, 2002.
• Accinelli RA, Alvarez LM, Diaz J, Yshii C, Aliaga A, Chavez W, Cornejo M, Chirinos E, Martinez H, Gayoso O. Tuberculosis among health-care workers of a general hospital in Lima, Peru. American Journal of Respiratory and Critical Care Medicine, 163:A965, 2001. 

Research

Peer-reviewed:

• Chan A, Balasubramanian M, Blackledge W, Mohammad OM, Alvarez L, Boss GR, Bigby TD. Cobinamide is superior to other treatments in a mouse model of cyanide poisoning. Clin Toxicol (Phila), 48:709-717, 2010. 
• KE Broderick, L Alvarez, M Balasubramanian, DD Belke, A Makino, A Chan, VL Woods Jr., WH Dillmann, VS Sharma, RB Pilz, TD Bigby and GR Boss. Nitrosyl-Cobinamide, a New and Direct Nitric Oxide–Releasing Drug Effective In Vivo. Experimental Biology and Medicine, 232:1432-1440, 2007.

Non-funded research:

• Impact of functional endoscopic sinus surgery on cystic fibrosis. Co-investigator with: Julie Biller MD, Diana Quintero MD, David Poetker MD and Todd Loehrl MD

Industry-sponsored research:

• Co-Investigator with Vertex Pharmaceuticals: A phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of VX-770 in subjects with cystic fibrosis and the G551D mutation. Principal investigator at Medical College of Wisconsin: Julie Biller MD
• Co-Investigator with Insmed: TR02112: a phase 3 randomized, double blind, placebo controlled study of liposomal amikacin for inhalation (Arikace) in patients with recalcitrant nontuberculous mycobacterial lung diseases. Principal investigator at University of Miami: Matthias Salathe MD
• Co-investigator with Abbvie, Janssen Pharmaceuticals, Aptalis Pharma,Iinc.: A long term prospective observational safety study of the incidence of and risk factors for fibrosing colonopathy in us patients with cystic fibrosis treated with pancreatic enzyme replacement therapy: A harmonized protocol across sponsors. Principal investigator at University of Miami: Matthias Salathe MD 
• Co-investigator with KaloBios Pharmaceuticals Inc: KB001A-05. A phase 2, randomized, double-blind, placebo-controlled, repeat-dose study of KB001-A in subjects with cystic fibrosis infected with Pseudomonas aeruginosa. Principal investigator at University of Miami: Matthias Salathe MD 
• Co-investigator with Gilead Sciences, Inc.: GS-US-205-0170. A phase 3, randomized, double-blind, placebo-controlled, multicenter study of aztreonam for inhalation solution (AZLI) in a continuous alternating therapy (CAT) regimen of inhaled antibiotics for the treatment of chronic pulmonary Pseudomonas aeruginosa infection in subjects with cystic fibrosis. Principal investigator at University of Miami: Matthias Salathe MD 
• Co-investigator with Savara Pharmaceuticals: SAV00502. A phase 2, randomized, double blind, placebo controlled study of Aerovanc for the treatment of persistent methicillin resistant Staphylococcus aureus lung infection in cystic fibrosis patients. Principal investigator at University of Miami: Matthias Salathe MD
• Co-investigator with Vertex Pharmaceuticals: A phase 3, randomized, double blind, placebo controlled, parallel group study to evaluate the efficacy and safety of lumacaftor monotherapy and in combination with ivacaftor in subjects aged 12 years and older with cysticfibrosis, homozygous for the F508del CFTR mutation. Principal investigator at University of Miami: Matthias Salathe MD 
• Co-investigator with Janssen Pharmaceuticals: JSPP1201. A point prevalence study to evaluate the prevalence of antibodies to selected porcine viruses in patients with cystic fibrosis who are receiving porcine derived pancreatic enzyme replacement therapy: A harmonized protocol across sponsors. Principal investigator at University of Miami: Matthias Salathe MD
• Co-investigator with Vertex Pharmaceuticals: A phase 2, multicenter, double-blinded, placebo-controlled, multiple-dose study to evaluate safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of lumacaftor monotherapy, and lumacaftor and ivacaftor combination therapy in subjects with cystic fibrosis, homozygous or heterozygous for the F508del CFTR mutation. Principal investigator at University of Miami: Matthias Salathe MD 
• Co-investigator with Vertex Pharmaceuticals: VX12809105: A phase 3, rollover study to evaluate the safety and efficacy of long term treatment with lumacaftor in combination with ivacaftor. Principal investigator at University of Miami: Matthias Salathe MD

Professional Organizations

• American Thoracic Society
• European Respiratory Society